Fresenius Medical Care (FMCQF) officer Olga Renkewitsch files baseline Form 3

Rhea-AI Filing Summary

Fresenius Medical Care AG filed an initial Form 3 for officer Olga Renkewitsch, indicating her status as an executive (title referenced as “See Remarks”). The provided data show no reported transactions, no derivative positions, and no specific share holdings, serving mainly as a baseline ownership disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/18/2026 - 10:01 AM Learn about SEC filing dates

FAQ

What does the Fresenius Medical Care (FMCQF) Form 3 for Olga Renkewitsch show?

The Form 3 records Olga Renkewitsch as an officer of Fresenius Medical Care AG. It serves as an initial ownership baseline and, in this data, reports no specific share holdings or transactions for her.

Are any Fresenius Medical Care (FMCQF) insider share purchases or sales reported in this Form 3?

No insider share purchases or sales are reported in this Form 3. The transaction summary shows zero buy, sell, acquire, dispose, gift, or tax-withholding entries, indicating no activity disclosed in this filing.

Does the Fresenius Medical Care (FMCQF) Form 3 disclose derivative positions for Olga Renkewitsch?

This Form 3 does not disclose any derivative positions for Olga Renkewitsch. The derivative summary is empty and the exercise-related counts are zero, meaning no options, warrants, or similar instruments are listed here.

What role does Olga Renkewitsch hold at Fresenius Medical Care (FMCQF) in this Form 3?

The Form 3 identifies Olga Renkewitsch as an officer of Fresenius Medical Care AG. Her specific officer title is referenced as “See Remarks,” indicating further detail appears in the remarks section outside the structured data.

Why is a Form 3 important for Fresenius Medical Care (FMCQF) investors?

Form 3 is the initial insider ownership statement for a company’s officers, directors, or major holders. It establishes a baseline from which future insider Forms 4 and 5 can be compared to track changes in reported holdings.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Renkewitsch Olga

(Last) (First) (Middle)

ELSE-KROENER STRASSE 3

(Street)

BAD HOMBURG 65191

(City) (State) (Zip)

GERMANY

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Fresenius Medical Care AG [ FMS ]

3a. Foreign Trading Symbol
[FME]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Head of Global Accounting and Controlling (Chief Accounting Officer). Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Robert A. Grauman, as attorney-in-fact for Olga Renkewitsch	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)